Clinical Trial Update: Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Iparomlimab/Tuvonralimab with standard chemotherapy and Olaparib in platinum-sensitive recurrent ovarian cancer; currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-sensitive Recurrent Ovarian Cancer

Drugs mentioned

• Iparomlimab/Tuvonralimab
• Olaparib (Olaparib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING